pSivida Reports Iluvien for DME Approved in Poland
pSivida Corp. announced that the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland has granted marketing authorization to Iluvien for the treatment of vision impairment associated with diabetic macular edema (DME) considered insufficiently responsive to available therapies, according to a company news release. This marks the completion of the latest round of EU authorizations with Iluvien now approved in 17 European countries.
Iluvien is currently being sold in the United States, United Kingdom, Germany and Portugal. pSivida is entitled to 20% of net profits of Iluvien sales by its licensee on a country-by-country, quarter-by-quarter basis.
You must be logged in to leave a comment.